Research programme: FASN inhibitors - 3-V Biosciences

Drug Profile

Research programme: FASN inhibitors - 3-V Biosciences

Alternative Names: TVB-3664

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3-V Biosciences
  • Class Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Non-alcoholic steatohepatitis; Parainfluenza virus infections; Solid tumours
  • No development reported Hepatitis C; Herpes simplex virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 20 Oct 2017 Pharmacodynamics data from a preclinical trial in non-alcoholic steatohepatitis presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 16 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top